Abstract
Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
